I believe if the OnCarylytics/Blincyto combo trial works, then there is no way Amgen is going to leave it at that. That would indeed open up the 90% solid tumor market to them. The data just need to be compelling and Amgen would act. And since OnCarlytics/Blincyto is the first mover, all the more Amgen will want to get a wiggle on to be first in class.
I believe if the OnCarylytics/Blincyto combo trial works, then...
-
- There are more pages in this discussion • 2,586 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5438 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 49219 | 5 |
View Market Depth
| Last trade - 09.58am 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable